Ascendis Pharma A/S (NASDAQ:ASND) Receives $216.07 Average Price Target from Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been given an average rating of "Buy" by the fifteen analysts that are currently covering the firm, MarketBeat.com reports. Fifteen research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $216.07.

Several brokerages recently commented on ASND. Royal Bank of Canada raised their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a report on Friday, May 2nd. Evercore ISI lifted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research report on Friday, May 2nd. The Goldman Sachs Group upped their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Finally, Wedbush lifted their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday, May 2nd.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several large investors have recently made changes to their positions in ASND. T. Rowe Price Investment Management Inc. raised its holdings in Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after purchasing an additional 960,504 shares during the last quarter. Capital International Investors boosted its stake in shares of Ascendis Pharma A/S by 35.7% in the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock valued at $394,183,000 after purchasing an additional 753,859 shares during the last quarter. RA Capital Management L.P. grew its position in shares of Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after buying an additional 402,316 shares during the period. Adage Capital Partners GP L.L.C. bought a new stake in shares of Ascendis Pharma A/S during the first quarter worth approximately $51,029,000. Finally, Vestal Point Capital LP lifted its holdings in Ascendis Pharma A/S by 108.0% in the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock valued at $71,588,000 after buying an additional 270,000 shares during the period.

Ascendis Pharma A/S Stock Up 0.2%

Ascendis Pharma A/S stock traded up $0.33 during mid-day trading on Wednesday, reaching $157.93. The company had a trading volume of 85,231 shares, compared to its average volume of 510,070. The firm has a market cap of $9.63 billion, a price-to-earnings ratio of -22.24 and a beta of 0.41. The company has a 50 day moving average of $157.15 and a 200-day moving average of $142.64. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million. On average, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.